Wang Ya-Yun, Zhang Jing, Zhuang Xiong, Jin Qiu-Yan, Liu Liang-Qing
Department of Imaging, Wujin Clinical College of Xuzhou Medical University Changzhou 213002, Jiangsu, China.
Jiangsu Key Laboratory of Encephalopathy Bioinformatics Xuzhou 221004, Jiangsu, China.
Am J Cancer Res. 2024 Oct 15;14(10):4855-4867. doi: 10.62347/WYNK6968. eCollection 2024.
To investigate the use of hepatocyte-specific contrast agent Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the diagnosis and efficacy evaluation of patients with early-stage hepatocellular carcinoma.
A retrospective clinical study was conducted on 157 patients diagnosed with stage Ia-Ib liver cancer. Of these, 100 patients underwent preoperative EOB-MRI, while 57 patients underwent contrast-enhanced computerized tomography (CECT). The study compared the accuracy, sensitivity, and specificity of these two imaging modalities in diagnosing early-stage hepatocellular carcinoma. In the EOB-MRI group, 100 patients underwent radiofrequency ablation or interventional procedures, and imaging data were collected post-scan. The following arterial and hepatobiliary phase enhancement features were analyzed: length-diameter difference (LDD), signal intensity ratio of metastases to liver parenchyma (RatioM/L), relative signal intensity difference (RSID), normalized relative enhancement (NRE), contrast-to-noise ratio (CNR), and apparent diffusion coefficient (ADC) values. Based on treatment outcomes, patients were categorized into high and low response rate groups, and the imaging parameters between these two groups were compared. Univariate and multivariate analyses were performed to evaluate the significance of these parameters in predicting patient outcomes.
The accuracy of lesion detection by EOB-MRI was 97.4%, significantly higher than that of CECT (80.0%) (P < 0.05). The area under the curve (AUC) for the EOB-MRI group was 0.923 (95% CI: 0.784-1.000), with a sensitivity of 97.4% and a specificity of 83.3%. In comparison, the AUC for the CECT group was 0.712 (95% CI: 0.582-0.843), with a sensitivity of 77.2% and a specificity of 65.2%. The median response rate of patients with early-stage hepatocellular carcinoma to systemic therapy was 60% (range: 36%-81%). Using 60% as the cut-off value, patients were divided into a high response rate group (n = 53) and a low response rate group (n = 47). Univariate and multivariate logistic regression analyses of the EOB-MRI parameters in both groups identified ADC and NRE as independent predictors for assessing the treatment efficacy of early-stage hepatocellular carcinoma.
EOB-MRI is effective for both the diagnosis and evaluation of treatment efficacy in early-stage hepatocellular carcinoma.
探讨肝细胞特异性对比剂钆塞酸二钠增强磁共振成像(EOB-MRI)在早期肝细胞癌患者诊断及疗效评估中的应用。
对157例诊断为Ia-Ib期肝癌的患者进行回顾性临床研究。其中,100例患者术前行EOB-MRI检查,57例患者行对比增强计算机断层扫描(CECT)。该研究比较了这两种成像方式在诊断早期肝细胞癌方面的准确性、敏感性和特异性。在EOB-MRI组中,100例患者接受了射频消融或介入治疗,并在扫描后收集成像数据。分析了以下动脉期和肝胆期强化特征:长径差(LDD)、转移灶与肝实质信号强度比(RatioM/L)、相对信号强度差(RSID)、标准化相对强化(NRE)、对比噪声比(CNR)及表观扩散系数(ADC)值。根据治疗结果,将患者分为高反应率组和低反应率组,并比较两组之间的成像参数。进行单因素和多因素分析以评估这些参数在预测患者预后中的意义。
EOB-MRI检测病灶的准确性为97.4%,显著高于CECT(80.0%)(P<0.05)。EOB-MRI组的曲线下面积(AUC)为0.923(95%CI:0.784-1.000),敏感性为97.4%,特异性为83.3%。相比之下,CECT组的AUC为0.712(95%CI:0.582-0.843),敏感性为77.2%,特异性为65.2%。早期肝细胞癌患者全身治疗的中位反应率为60%(范围:36%-81%)。以60%为临界值,将患者分为高反应率组(n=53)和低反应率组(n=47)。对两组中EOB-MRI参数进行单因素和多因素逻辑回归分析,确定ADC和NRE为评估早期肝细胞癌治疗疗效的独立预测因子。
EOB-MRI对早期肝细胞癌的诊断及治疗疗效评估均有效。